At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 7 enrolled
Drug / intervention
Ranibizumab +1 moredrug
Likely dose
Ranibizumab 0.3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
In Brief
A Phase 1 clinical trial evaluating Ranibizumab for Choroidal Neovascularization. Completed, enrolled 7 participants across 1 site.
Detailed Summary
This research is being done to look at the effects of an experimental drug, ranibizumab, on a condition called "predominantly hemorrhagic subfoveal choroidal neovascularization (CNV)" due to wet age-related macular degeneration. A predominantly hemorrhagic CNV lesion is diagnosed when at least 50% of the choroidal neovascular lesion is occupied by blood under the retina. We want to find out if injections of ranibizumab into the eye will help patients with this condition.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChoroidal Neovascularization
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
First PostedAug 2006
Primary CompletionJun 2008
Study CompletionMay 2009
TodayJul 2026
First PostedAug 15, 2006
Enrollment StartAug 1, 2006
Primary CompletionJun 1, 2008
Study CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.9 years ago
Interventions
Ranibizumabdrug
0.3 mg/0.05 ml dose
Ranibizumabdrug
0.5 mg/0.05 ml dose